Moors & Cabot, Inc. Astrazeneca PLC Transaction History

Moors & Cabot, Inc.

$2.02 Billion
Q4 2024

A detailed history of Moors & Cabot, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Moors & Cabot, Inc. holds 8,091 shares of AZN stock, worth $627,861. This represents 0.03% of its overall portfolio holdings.

Number of Shares

8,091

Previous 7,191 12.52%

Holding current value

$627,861

Previous $560,000 5.36%

% of portfolio

0.03%

Previous 0.03%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	BUY	$63.2 - $79.58 $56,880 - $71,622	900 Added 12.52%	8,091 $530,000
Q3 2024 Nov 08, 2024	BUY	$76.67 - $87.62 $9,277 - $10,602	121 Added 1.71%	7,191 $560,000
Q2 2024 Aug 09, 2024	SELL	$66.81 - $80.83 $91,195 - $110,332	-1,365 Reduced 16.18%	7,070 $551,000
Q1 2024 May 08, 2024	BUY	$61.03 - $69.57 $671 - $765	11 Added 0.13%	8,435 $571,000
Q4 2023 Feb 14, 2024	BUY	$61.89 - $69.28 $3,589 - $4,018	58 Added 0.69%	8,424 $567,000
Q3 2023 Nov 07, 2023	BUY	$64.85 - $71.7 $22,048 - $24,378	340 Added 4.24%	8,366 $566,000
Q2 2023 Aug 09, 2023	SELL	$69.91 - $75.81 $194,209 - $210,600	-2,778 Reduced 25.71%	8,026 $574,000
Q1 2023 May 04, 2023	BUY	$63.15 - $71.6 $2,715 - $3,078	43 Added 0.4%	10,804 $749,000
Q4 2022 Feb 09, 2023	BUY	$54.21 - $70.44 $158,293 - $205,684	2,920 Added 37.24%	10,761 $729,000
Q4 2022 Feb 06, 2023	SELL	$54.21 - $70.44 $148,698 - $193,216	-2,743 Reduced 25.92%	7,841 $531,000
Q3 2022 Nov 07, 2022	SELL	$53.02 - $135.75 $28,895 - $73,983	-545 Reduced 4.9%	10,584 $580,000
Q2 2022 Aug 08, 2022	BUY	$59.26 - $71.14 $17,066 - $20,488	288 Added 2.66%	11,129 $735,000
Q1 2022 May 13, 2022	BUY	$55.72 - $67.12 $16,270 - $19,599	292 Added 2.77%	10,841 $719,000
Q4 2021 Feb 14, 2022	BUY	$54.02 - $63.83 $29,927 - $35,361	554 Added 5.54%	10,549 $614,000
Q3 2021 Dec 08, 2021	SELL	$55.56 - $60.79 $65,338 - $71,489	-1,176 Reduced 10.53%	9,995 $600,000
Q3 2021 Nov 05, 2021	BUY	$55.56 - $60.79 $45,059 - $49,300	811 Added 7.83%	11,171 $598,000
Q2 2021 Aug 10, 2021	SELL	$48.42 - $60.18 $38,009 - $47,241	-785 Reduced 7.04%	10,360 $621,000
Q1 2021 May 12, 2021	SELL	$47.16 - $54.44 $7,215 - $8,329	-153 Reduced 1.35%	11,145 $554,000
Q4 2020 Feb 11, 2021	BUY	$48.52 - $58.02 $14,410 - $17,231	297 Added 2.7%	11,298 $563,000
Q3 2020 Nov 09, 2020	SELL	$53.07 - $61.1 $128,429 - $147,862	-2,420 Reduced 18.03%	11,001 $603,000
Q2 2020 Aug 13, 2020	SELL	$43.1 - $55.31 $3,189 - $4,092	-74 Reduced 0.55%	13,421 $706,000
Q1 2020 May 12, 2020	SELL	$37.79 - $51.33 $61,862 - $84,027	-1,637 Reduced 10.82%	13,495 $600,000
Q4 2019 Jan 28, 2020	BUY	$42.46 - $50.46 $5,137 - $6,105	121 Added 0.81%	15,132 $756,000
Q3 2019 Oct 22, 2019	BUY	$40.12 - $45.47 $5,937 - $6,729	148 Added 1.0%	15,011 $665,000
Q2 2019 Jul 18, 2019	BUY	$37.28 - $41.68 $103,750 - $115,995	2,783 Added 23.04%	14,863 $615,000
Q1 2019 May 06, 2019	SELL	$35.49 - $43.02 $428,719 - $519,681	-12,080 Reduced 50.0%	12,080 $488,000
Q1 2019 May 01, 2019	BUY	$35.49 - $43.02 $472,336 - $572,553	13,309 Added 122.65%	24,160 $976,000
Q4 2018 Feb 13, 2019	SELL	$36.86 - $41.49 $11,058 - $12,447	-300 Reduced 2.69%	10,851 $410,000
Q3 2018 Nov 14, 2018	SELL	$34.76 - $39.72 $764 - $873	-22 Reduced 0.2%	11,151 $442,000
Q2 2018 Aug 14, 2018	SELL	$34.55 - $37.05 $46,400 - $49,758	-1,343 Reduced 10.73%	11,173 $396,000
Q1 2018 May 18, 2018	BUY	$32.97 - $36.63 $4,615 - $5,128	140 Added 1.13%	12,516 $438,000
Q4 2017 Feb 13, 2018	SELL	$32.09 - $34.78 $76,342 - $82,741	-2,379 Reduced 16.12%	12,376 $427,000
Q3 2017 Nov 16, 2017	SELL	$28.96 - $34.0 $92,237 - $108,290	-3,185 Reduced 17.75%	14,755 $501,000
Q2 2017 Aug 15, 2017	BUY	N/A	17,940	17,940 $610,000

Others Institutions Holding AZN

# of Institutions

1,367

Shares Held

512M

Call Options Held

6.08M

Put Options Held

4.44M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $240B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.

Account